Balanescu AR, Citera G, Pascual-Ramos V, et al. Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label randomised controlled ORAL Surveillance trial. Ann Rheum Dis 2022;81:1491–503. doi:10.1136/ard-2022-222405.
In Table 3, there was a typographical error in the upper confidence interval of the hazard ratio for ‘history of extra-articular disease: yes versus no’ as a risk factor for serious infection events with tofacitinib 5 mg two times per day. The incorrect value was 1.19, this has now been corrected to 1.91.
The value has now been corrected in the online publication.